07/30/2026 | Press release | Distributed by Public on 07/30/2026 04:10
In the world of financial exchanges, the market is asking investors to pay more for slower growth, a puzzle that pits a profitable fortress against a discounted challenger.
The market currently charges 21.7 times operating profit for a stake in CME (CME) Group, but only 18.5 times for its industry peer S&P Global (SPGI). These are two of the market's primary ways to own the infrastructure of finance, yet the one growing revenue slower now costs more. The question for any investor in this space is what, exactly, CME's premium still buys.
This valuation gap is a recent reversal. A year ago, CME was the cheaper of the two. The roles have since flipped, not because CME's multiple soared, but because SPGI's collapsed. That sharp de-rating of a faster-growing peer puts the choice in focus: is SPGI a genuine bargain, or is its lower price a warning sign about its business?
CME's premium buys a fortress of profitability.
CME's case for its higher multiple rests on its dominant position and immense profitability. The company converts a huge 65.1% of its revenue into operating profit, a margin far exceeding SPGI's 41.6%. This efficiency is the financial result of a deep competitive moat built around its core clients. Management is clear on this point, stating that through the first half of 2026, 94% of its volume came from institutional customers.
These are not fickle retail traders. They are large-scale risk managers who rely on CME's deep liquidity pools for essential hedging. Management has been adamant that these core users have shown no interest in trendy products like perpetual futures, which it views as unsuitable for institutional risk management. Instead, CME is focused on innovation for its base, planning to launch a Compute Futures market later this year and a Treasury Link platform in the fourth quarter to better serve its sophisticated clientele.
The key numbers side by side today:
| Metric | CME | SPGI | ICE |
|---|---|---|---|
| P/OpInc* | 21.7x | 18.5x | 16.0x |
| LTM OpInc Growth | 4.8% | 16.2% | 19.4% |
| 3Y Avg OpInc Growth | 11.9% | 22.5% | 13.7% |
| LTM Revenue Growth | 5.1% | 9.7% | 7.3% |
| 3Y Avg Revenue Growth | 9.0% | 10.2% | 10.8% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:
| Metric | CME | SPGI | ICE |
|---|---|---|---|
| P/OpInc* | 22.8x | 27.9x | 23x |
| LTM OpInc Growth | 15.5% | 20.8% | 12.2% |
| 3Y Avg OpInc Growth | 13.8% | 19.2% | 7.9% |
| LTM Revenue Growth | 11.2% | 10.7% | 19.1% |
| 3Y Avg Revenue Growth | 10.0% | 15.7% | 10.0% |
OpInc = Operating Income
Paying the premium means forgoing faster growth.
By paying for CME's stability, an investor gives up direct exposure to SPGI's superior growth. S&P Global expanded its revenue by 9.7% over the last twelve months, outpacing CME's 5.1% clip. That growth comes from a different business model, one heavily weighted toward data, analytics, and credit ratings, which gives it a broad footprint across the financial industry.
However, SPGI's cheaper multiple comes with a clear caution flag. The company recently cut its forward guidance for revenue and earnings per share, a signal that has clearly weighed on its valuation. The stock's -20.2% return over the last year reflects this uncertainty.
The decision hinges on institutional loyalty versus discounted growth.
The choice between these two companies comes down to a single forward-looking question: Do you believe CME's institutional fortress is durable enough to justify its slower growth, or is SPGI's discounted, faster-growing model a more strong opportunity despite its recent stumbles? Paying up for CME is a bet on the enduring power of its client relationships and its highly profitable, focused business model.
Opting for SPGI is a wager that its guidance cut is a temporary issue and that its faster top-line growth will ultimately be rewarded. The most tangible test of CME's strategy will be the adoption of its new products. The performance of its pioneering `Compute Futures` market, set to launch later this year, will offer a clear signal of whether its brand of innovation can still command a premium.
Rather Compare Them On Your Own Terms?
You can line CME and S&P Global and Intercontinental Exchange up directly on the CME peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Financial Exchanges & Data names you hold. Or, if you would rather not pick a side at all, a U.S. broker-dealers & securities exchanges ETF like IAI holds both CME and S&P Global and Intercontinental Exchange alongside the rest of the group.
The Better Bet Is Still One Bet
Picking the statistically better stock improves the odds, it does not change how much rides on one name. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.